SION vs SKYE

Sionna Therapeutics, Inc. vs Skye Bioscience, Inc. — Valuation Comparison 2026

SION

Biotechnology
Sionna Therapeutics, Inc.
Quality
4.3
out of 10
Value Trap
Price
$42.80
Last close
Models
10/13
Active
VS

SKYE

Biotechnology
Skye Bioscience, Inc.
Quality
3.6
out of 10
Value Trap
30
LOW
Price
$0.85
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType SION Fair ValueSION Upside SKYE Fair ValueSKYE Upside
Bayesian DCF Intrinsic $8.06 -81.2% $0.21 -74.8%
Earnings Power Value Intrinsic $15.97 -58.1%
EROIC Spread Intrinsic $•••.•• ••.•% $•••.•• ••.•%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
Markov DDM Intrinsic $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $4.47 -88.6% $1.84 +116.7%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for SION vs SKYE — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

SION vs SKYE — Which Stock Is More Undervalued?

SION scores higher with a 4.3/10 quality rating vs SKYE's 3.6/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Sionna Therapeutics, Inc. (SION) and Skye Bioscience, Inc. (SKYE) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

SION currently trades at $42.80 with a QOC of 4.3/10, while SKYE trades at $0.85 with a QOC of 3.6/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).